|Videos|September 29, 2022
The Progression of Myelodysplastic Syndrome to Acute Myeloid Leukemia (AML)
Author(s)Hetty E. Carraway, MD, Eytan M. Stein, MD
Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.
Advertisement
Episodes in this series
Advertisement
Related to this article
The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA granted orphan drug designation to Cardiff Oncology’s PLK1 inhibitor onvansertib for relapsed or refractory CMML after early phase 1 activity.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5